<akomaNtoso xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"
            xmlns:fmx="http://formex.publications.europa.eu/schema/formex-05.21-20110601.xd"
            xmlns:leos="urn:eu:europa:ec:leos"
            xmlns:xs="http://www.w3.org/2001/XMLSchema">
   <bill name="">
      <meta xmlns:fn="http://www.w3.org/2005/xpath-functions">
         <identification source="~COM">
            <FRBRWork>
               <FRBRthis value=""/>
               <FRBRuri value=""/>
               <FRBRdate date="2999-01-01" name=""/>
               <FRBRauthor href=""/>
               <FRBRcountry value=""/>
            </FRBRWork>
            <FRBRExpression>
               <FRBRthis value=""/>
               <FRBRuri value=""/>
               <FRBRdate date="2999-01-01" name=""/>
               <FRBRauthor href=""/>
               <FRBRlanguage language="eng"/>
            </FRBRExpression>
            <FRBRManifestation>
               <FRBRthis value=""/>
               <FRBRuri value=""/>
               <FRBRdate date="2999-01-01" name=""/>
               <FRBRauthor href=""/>
            </FRBRManifestation>
         </identification>
      </meta>
      <preface>
         <longTitle>
            <p>
               <docStage/>
               <docType>COMMISSION REGULATION (EU) 2020/1684</docType>of 12 November 2020<docPurpose>amending Annex VI to Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products</docPurpose>
            </p>
         </longTitle>
         <container name="EEArelevance">
            <p>(Text with EEA relevance)</p>
         </container>
      </preface>
      <preamble>
         <formula name="actingEntity">
            <p>THE EUROPEAN COMMISSION,</p>
         </formula>
         <citations>
            <citation>
               <p>Having regard to the Treaty on the Functioning of the European Union,</p>
            </citation>
            <citation>
               <p>Having regard to Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products<authorialNote placement="bottom" marker="1">
                     <p>OJ L 342, 22.12.2009, p. 59.</p>
                  </authorialNote>, and in particular Article 31(2) thereof,</p>
            </citation>
         </citations>
         <recitals xml:id="recs_d234e71">
            <intro>
               <p>Whereas:</p>
            </intro>
            <recital xml:id="rec_d234e74">
               <num>(1)</num>
               <p>The Scientific Committee on Consumer Safety (SCCS) concluded in its opinion of 13 December 2019<authorialNote placement="bottom" marker="2">
                     <p>SCCS/1605/19.</p>
                  </authorialNote> (&apos;the SCCS opinion&apos;) that the use of Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate as a UV filter in cosmetic products at a maximum concentration of 3 % is safe. Inhalation toxicity was not assessed in the SCCS opinion because no data were provided. Hence, the SCCS opinion is not applicable to any cosmetic product in form of spray that could lead to exposure of the end-user&apos;s lungs by inhalation.</p>
            </recital>
            <recital xml:id="rec_d234e90">
               <num>(2)</num>
               <p>The SCCS also concluded in its opinion that Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate is a secondary amine, and thus is prone to nitrosation and formation of nitrosamine. It should not be used in combination with nitrosating substances. The nitrosamine content should be less than 50 ppb.</p>
            </recital>
            <recital xml:id="rec_d234e96">
               <num>(3)</num>
               <p>In light of the SCCS opinion and in order to take into account technical and scientific progress, the use of Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate as a UV filter in cosmetic products should be authorised at a maximum concentration of 3 %, except in applications that may lead to exposure of the end-user&apos;s lungs by inhalation.</p>
            </recital>
            <recital xml:id="rec_d234e102">
               <num>(4)</num>
               <p>Annex VI to Regulation (EC) No 1223/2009 should therefore be amended accordingly.</p>
            </recital>
            <recital xml:id="rec_d234e108">
               <num>(5)</num>
               <p>The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Cosmetic Products,</p>
            </recital>
         </recitals>
         <formula name="enactingFormula">
            <p>HAS ADOPTED THIS REGULATION:</p>
         </formula>
      </preamble>
      <body>
         <article xml:id="art_d234e117">
            <num>Article 1</num>
            <heading/>
            <paragraph>
               <content>
                  <p>Annex VI to Regulation (EC) No 1223/2009 is amended in accordance with the Annex to this Regulation.</p>
               </content>
            </paragraph>
         </article>
         <article xml:id="art_d234e122">
            <num>Article 2</num>
            <heading/>
            <paragraph>
               <content>
                  <p>This Regulation shall enter into force on the twentieth day following that of its publication in the <i>Official Journal of the European Union</i>.</p>
               </content>
            </paragraph>
         </article>
         <clause>
            <content>
               <p>This Regulation shall be binding in its entirety and directly applicable in all Member States.</p>
            </content>
         </clause>
      </body>
      <conclusions>
         <p>Done at Brussels, 12 November 2020.</p>
         <block name="signatory">
            <signature>
               <organization refersTo="">For the Commission</organization>
               <role refersTo="">The President</role>
               <person refersTo="">Ursula VON DER LEYEN</person>
            </signature>
         </block>
      </conclusions>
   </bill>
</akomaNtoso>
